ASX:CYC Cyclopharm (CYC) Stock Price, News & Analysis → Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad) Free CYC Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume10,000 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend Yield0.56%Price TargetN/A Stock AnalysisStock Analysis Get Cyclopharm alerts: Email Address Ad Chaikin AnalyticsWall Street Legend Issues New NVDA WarningLegendary Stockpicker: "Buy this A.I. stock NOW" His award-winning system pinpointed NVDA and META before both stocks doubled. Now it's flashing "BUY" on this under-the-radar A.I. stock.Click here for the stock details About CyclopharmCyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. It operates through Technegas and Molecular Imaging segments. The Technegas segment offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. This segment also distributes products to the diagnostic imaging sector. The Molecular Imaging segment provides radiopharmaceuticals that are used by physicians in the detection of cancer, neurological disorders, and cardiac diseases. The company serves nuclear medicine departments. Cyclopharm Limited was founded in 1986 and is headquartered in Kingsgrove, Australia.Read More Ad Chaikin AnalyticsWall Street Legend Issues New NVDA WarningLegendary Stockpicker: "Buy this A.I. stock NOW" His award-winning system pinpointed NVDA and META before both stocks doubled. Now it's flashing "BUY" on this under-the-radar A.I. stock.Click here for the stock details CYC Stock News HeadlinesJanuary 11, 2023 | finance.yahoo.comWe're Interested To See How Cyclopharm (ASX:CYC) Uses Its Cash Hoard To GrowJanuary 11, 2023 | finance.yahoo.comFurther weakness as Cyclopharm (ASX:CYC) drops 13% this week, taking one-year losses to 59%April 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.January 11, 2023 | finance.yahoo.comCyclopharm's (ASX:CYC) investors will be pleased with their favorable 42% return over the last five yearsSee More Headlines Receive CYC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cyclopharm and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Medical Devices Sub-IndustryN/A Current SymbolASX:CYC CUSIPN/A CIKN/A Webwww.cyclopharm.com.au Phone61 2 9541 0411FaxN/AEmployees87Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,700,000.00 Net Margins-17.32% Pretax MarginN/A Return on Equity-13.67% Return on Assets-12.08% Debt Debt-to-Equity Ratio13.10 Current Ratio3.48 Quick Ratio4.68 Sales & Book Value Annual Sales$27.14 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow8.40 Book ValueA$0.34 per share Price / BookN/AMiscellaneous Outstanding Shares94,100,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta0.80 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. James S. McBrayer AIM (Age 59)BSPharm, F.A.C.I.D., FAICD, GDM, CEO, MD, Company Secretary & Director Comp: $624.04kMr. Mathew FaragChief Operating OfficerMr. Graham N. PhillipsFinance ManagerMs. Sally-Ann CorneliusHead of SalesMs. Niamh McAreeHead of Quality and RegulatoryMr. Chris QuinnHead of ServiceMs. Sui Ling Cheah (Age 54)Financial Controller Comp: $63.73kMr. Lynn McLauchlinGeneral Manager of CanadaMr. Gary T. SomervilleQuality & Regulatory ManagerMore ExecutivesKey Competitors4DMedicalASX:4DXAdheriumASX:ADRAinosNASDAQ:AIMDWAllegra Medical TechnologiesASX:AMTAnalyticaASX:ALTView All CompetitorsInsidersJames McBrayerSold 200,000 sharesTotal: $262,000.00 ($1.31/share)David HeaneyBought 10,000 shares on 10/31/2023Total: $20,400.00 ($2.04/share) CYC Stock Analysis - Frequently Asked Questions Is Cyclopharm a good dividend stock? Cyclopharm (ASX:CYC) pays an annual dividend of A$0.01 per share and currently has a dividend yield of 0.56%. Read our dividend analysis for CYC. This page (ASX:CYC) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap Profits“The Biggest Bubble of All Time” – Here’s What to Do.Chaikin AnalyticsYour Money is Not SafeAmerican Alternativetop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders Agency Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclopharm Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
